Multifunctional CD40L: pro- and anti-neoplastic activity

Tumor Biology

Volumn 35, Issue 10, 2014, Pages 9447-9457

  Korniluk, Aleksandra ^a   Kemona, Halina ^a   Dymicka Piekarska, Violetta ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Apoptosis; Cancer; CD40; CD40L; Inflammation

Indexed keywords

CD40 LIGAND; VASCULOTROPIN;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CELL; CANCER GROWTH; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNE RESPONSE; INFLAMMATION; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; SOLID TUMOR; TUMOR IMMUNITY; ANIMAL; METABOLISM; NEOPLASM;

ANIMALS; CD40 LIGAND; HUMANS; NEOPLASMS;

EID: 84919365511     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-2407-x     Document Type: Review

References (104)

1. Karpusas M, Hsu YM, Wang JH, Thompson J, Lederman S, Chess L, et al. 2 Å crystal structure of an extracellular fragment of human CD40 ligand. Structure. 1995;15:1031–9.
2. Villa A, Notarangelo LD, Di Santo JP, Macchi PP, Strina D, Frattini A, et al. Organization of the human CD40L gene: implications for molecular defects in X chromosome-linked hyper-IgM syndrome and prenatal diagnosis. Proc Natl Acad Sci. 1994;91:2110–4.
3. van Kooten C, Banchereau J. CD40-CD40 ligand. JLB. 2000;67:12–7.
4. Hsu YM, Lucci J, Su L, Ehrenfels B, Garber E, Thomas D. Heteromultimeric complexes of CD40 ligand are present on the cell surface of human T lymphocytes. J Biol Chem. 1997;272:911–5.
5. Graf D, Muller S, Korthauer U, van Kooten C, Weise C, Kroczek RA. A soluble form of TRAP (CD40 ligand) is rapidly released after T cell activation. Eur J Immunol. 1995;25:1749–54.
6. Prasad KS, Andre P, He M, Bao M, Manganello J, Phillips DR. Soluble CD40 ligand induces beta3 integrin tyrosine phosphorylation and triggers platelet activation by outside-in signaling. Proc Natl Acad Sci U S A. 2003;14:12367–71.
7. Andre P, Prasad KS, Denis CV, He M, Papalia JM, Hynes RO, et al. CD40L stabilizes arterial thrombi by a beta3 integrin-dependent mechanism. Nat Med. 2002;8:247–52.
8. Elgueta R, Benson MJ, de Vries VC, Wasiuk A, Guo Y, Noelle RJ. Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol Rev. 2009;229:152–72.
9. Henn V, Slupsky JR, Grafe M, Anagnostopoulos I, Förster R, Müller-Berghaus G, et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature. 1998;391:591–4.
10. Kawabe T, Matsushima M, Hashimoto N, Imaizumi K, Hasegawa Y. CD40/CD40 ligand interactions in immune responses and pulmonary immunity. Nagoya J Med Sci. 2011;73:69–78.
11. Loskoga AS, Eliopoulosb AG. The Janus faces of CD40 in cancer. Semin Immunol. 2009;21:301–7.
12. Bishop GA, Moore CR, Xie P, Stunz LL, Kraus ZJ. TRAF proteins in CD40 signaling. Adv Exp Med Biol. 2007;597:131–51.
13. Loskog A, Tötterman TH. CD40L—a multipotent molecule for tumor therapy. Endocr Metab Immune Disord-Drug Targets. 2007;7:23–8.
14. Saluk-Juszczak J, Królewska K. Rola szlaku CD40/CD40L w biologicznej aktywności płytek krwi. Część II. Przegląd Menopauzalny. 2010;6:371–5.
15. Krzesz R, Wagner AH, Cattaruzza M, Hecker M. Cytokine-inducible CD40 gene expression in vascular smooth muscle cells is mediated by nuclear factor κB and signal transducer and activation of transcription-1. FEBS Lett. 1999;453:191–6.
16. Wagner AH, Gebauer M, Pollok-Kopp B, Hecker M. Cytokine-inducible CD40 expression in human endothelial cells is mediated by interferon regulatory factor-1. Blood. 2002;99:520–5.
17. Dallman C, Johnson PW, Packham G. Differential regulation of cell survival by CD40. Apoptosis. 2003;8:45–53.
18. Srinivasan SK, Triemer HL, Kirk AD. Combination and adjuvant therapies to facilitate the efficacy of costimulatory blockade. In: Kaplan B, Burkhart GJ, Lakkis FG, editors. Immunotherapy in transplantation: principles and practice. Oxford: Wiley-Blackwell; 2012. p. 407–29.
19. Danese S, Sans M, Fiocchi C. The CD40/CD40L costimulatory pathway in Inflammatory Bowel Disease. Gut. 2004;53:1035–43.
20. Khanna R, Cooper L, Kienzle N, Moss DJ, Burrows SR, Khanna KK. Engagement of CD40 antigen with soluble CD40 ligand up-regulates peptide transporter expression and restores endogenous processing function in Burkitt’s lymphoma cells. J Immunol. 1997;159:5782–5.
21. Denese S, Fiocchi C. Platelet activation and the CD40/CD40L ligand pathway: mechanisms and implications for human diseases. Crit Rev Immunol. 2005;25:103–21.
22. Zhang Y, Cao HJ, Graf B, Meekins H, Smith TJ, Phipps RP. CD40 engagement up-regulates cyclooxygenase-2 expression and prostaglandin E2 production in human lung fibroblasts. J Immunol. 1998;160:1053–7.
23. Inwald DP, McDowall A, Peters MJ, Callard RE, Klein NJ, et al. CD40 is constitutively expressed on platelets and provides a novel mechanism for platelet activation. Circ Res. 2003;92:944–6.
24. Danese S, de la Motte C, Reyes BM, Sans M, Levine AD, Fiocchi C. T-cells trigger CD40-dependent platelet activation and granular RANTES release: a novel pathway for immune response amplification. J Immunol. 2004;172:2011–5.
25. Jinchuan Y, Zonggui W, Jinming C, Li L, Xiantao K. Upregulation of CD40-CD40 ligand system in patients with diabetes mellitus. Clin Chim Acta. 2004;339:85–90.
26. Lutgens E, Gorelik L, Daemen MJ, de Muinck ED, Grewal IS, Koteliansky VE, et al. Requirement for CD154 in the progression of atherosclerosis. Nat Med. 1999;5:1313–6.
27. Pamukcu B, Lip GYH, Snezhitskiy V, Shantsila E. The CD40-CD40L system in cardiovascular disease. Ann Med. 2011;43:331–40.
28. Schönbeck U, Varo N, Libby P, Buring J, Ridker PM. Soluble CD40L and cardiovascular risk in women. Circulation. 2001;104:2266–8.
29. Heeschen C, Dimmeler S, Hamm CW, van den Brand MJ, Boersma E, Zeiher AM, et al. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med. 2003;348:1104–11.
30. Bereznaya NM, Chekhun VF. Expression of CD40 andCD40L on tumor cells: their interaction and new approach to immunotherapy. Exp Oncol. 2007;29:1–12.
31. Tong AT, Stone MJ. Prospects for CD40-directed experimental therapy of human cancer. Cancer Gene Ther. 2003;10:1–13.
32. Bergmann S, Pandolfi PP. Giving blood: a new role for CD40 in tumorigenesis. J Exp Med. 2006;203:2409–12.
33. Murugaiyan G, Martin S, Saha B. CD40-induced counter current conduits for tumor escape or elimination? Trends Immunol. 2007;28:467–73.
34. Huang J, Jochems C, Talaie T, Anderson A, Jales A, Tsang KY, et al. Elevated serum soluble CD40 ligand in cancer patients may play an immunosuppressive role. Blood. 2012;120:3030–8.
35. Nishida N, Yano H, Nishida T, Kamura T, Kojiro M. Angiogenesis in cancer. Vasc Health Risk Manag. 2006;2:213–9.
36. French LE, Tschopp J. Defective death receptor signaling as a cause of tumor immune escape. Semin Cancer Biol. 2002;12:51–5.
37. Somasundaram R, Jacob L, Swoboda R, Caputo L, Song H, Basak S, et al. Inhibition of cytolytic T lymphocyte proliferation by autologous CD4+/CD25+ regulatory T cells in a colorectal carcinoma patient is mediated by transforming growth factor-h. Cancer Res. 2002;62:5267–72.
38. Berger CL, Tigelaar R, Cohen J, Mariwalla K, Trinh J, Wang N, et al. Cutaneous T-cell lymphoma: malignant proliferation of T-regulatory cells. Blood. 2005;105:1640–7.
39. Łuczyński W, Krawczuk-Rybak M, Stasiak-Barmuta A. Experimental and selected clinical aspects of active immunotherapy in leukemia. Postepy Hig Med Dosw. 2006;60:379–86.
40. Ning Y, Qian K, Qi C. Role of vascular endothelial growth factor receptor in the pro-proliferation activity of CD40-CD40L in AGS gastric cancer cells. Asian Biomed. 2010;4:797–802.
41. Miura S, Tatsuguchi A, Wada K, Takeyama H, Shinji Y, Hiratsuka T, et al. Cyclooxygenase-2-regulated vascular endothelial growth factor release in gastric fibroblasts. Am J Physiol Gastrointest Liver Physiol. 2004;287:444–51.
42. Tai YT, Li X, Tong X, Santos D, Otsuki T, Catley L, et al. Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma. Cancer Res. 2005;65:5898–906.
43. Farahani M, Treweeke AT, Toh CH, Till KJ, Harris RJ, Cawley JC, et al. Autocrine VEGF mediates the antiapoptotic effect of CD154 on CLL cells. Leukemia. 2005;19:524–30.
44. Byrd JC, Kipps TJ, Flinn IW, Cooper M, Odenike O, Bendiske J, et al. Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia. Leuk Lymphoma. 2012;53:2136–42.
45. Kluin-Nelemans HC, Beverstock GC, Mollevanger P, Wessels HW, Hoogendoorn E, Willemzeet R, et al. Proliferation and cytogenetic analysis of hairy cell leukemia upon stimulation via the CD40 antigen. Blood. 1994;84:3134–41.
46. Schattner EJ, Mascarenhas J, Bishop J, Yoo DH, Chadburn A, Crow MK, et al. CD4+ T-cell induction of Fas-mediated apoptosis in Burkitt’s lymphoma B cells. Blood. 1996;88:1375–82.
47. Garrone P, Neidhardt EM, Garcia E, Galibert L, van Kooten C, Banchereau J. Fas ligation induces apoptosis of CD40-activated human B lymphocytes. J Exp Med. 1995;182:1265–73.
48. Castillo R, Mascarenhas J, Telford W, Chadburn A, Friedman SM, Schattner EJ. Proliferative response of mantle cell lymphoma cells stimulated by CD40 ligation and IL-4. Leukemia. 2000;14:292–8.
49. Kato H, Kagami Y, Nakagawa M, Karnan S, Yatabe Y, Nakamura S, et al. IL-4/CD40L co-stimulation induces long-term proliferation for CD10-positive germinal centre anticancer activity B cell-like diffuse large B-cell lymphoma. Open Leuk J. 2010;3:60–8.
50. Pham LV, Tamayo AT, Yoshimura LC, Lo P, Terry N, Reid PS, et al. A CD40 signalosome anchored in lipid rafts leads to constitutive activation of NF-kappaB and autonomous cell growth in B cell lymphomas. Immunity. 2002;16:37–50.
51. Voorzanger-Rousselot N, Blay JY. Coexpression of CD40 and CD40L on B lymphoma and carcinoma cells: an autocrine anti-apoptotic role. Leuk Lymphoma. 2004;45:1239–45.
52. Voorzanger-Rousselot N, Alberti L, Blay JY. CD40L induces multidrug resistance to apoptosis in breast carcinoma and lymphoma cells through caspase independent and dependent pathways. BMC Cancer. 2006;18:75.
53. Hermann A, Rauch BH, Braun M, Schror K, Weber AA. Platelet CD40 ligand (CD40L)-subcellular localization, regulation of expression, and inhibition by clopidogrel. Platelets. 2001;12:74–82.
54. Yamaguchi H, Tanaka F, Sadanaga N, Ohta M, Inoue H, Mori M. Stimulation of CD40 inhibits Fas- or chemotherapy-mediated apoptosis and increases cell motility in human gastric carcinoma cells. Int J Oncol. 2003;23:1697–702.
55. Li R, Chen W-C, Pang X-Q, Hua C, Li L, Zhang X-G. Expression of CD40 and CD40L in gastric cancer tissue and its clinical significance. Int J Mol Sci. 2009;10:3900–17.
56. Jakobson E, Jonsson G, Bjorck P, Paulie S. Stimulation of CD40 in human bladder carcinoma cells inhibits anti-Fas/APO-1 (CD95)-induced apoptosis. Int J Cancer. 1998;77:849–53.
57. He S, Zhao H, Fei M, Wu Y, Wang L, Zhu X, et al. Expression of the co-signaling molecules CD40-CD40L and their growth inhibitory effect on pancreatic cancer in vitro. Oncol Rep. 2012;28:262–8.
58. Roselli M, Mineo TC, Basili S, Martini F, Mariotti S, Aloe S, et al. Soluble CD40 ligand plasma levels in lung cancer. Clin Cancer Res. 2004;10:610–4.
59. Amirkhosravi A, Amaya M, Desai H, Francis JL. Platelet-CD40 ligand interaction with melanoma cell and monocyte CD40 enhances cellular procoagulant activity. Blood Coagul Fibrinolysis. 2002;13:505–12.
60. Pinzon-Charry A, Schmidt CW, Lopez JA. The key role of CD40 ligand in overcoming tumor-induced dendritic cell dysfunction. Breast Cancer Res. 2006;8:402.
61. Esche C, Gambotto A, Satoh Y, Gerein V, Robbins PD, Watkins SC, et al. CD154 inhibits tumor-induced apoptosis in dendritic cells and tumor growth. Eur J Immunol. 1999;29:2148–55.
62. Medema JP, Schuurhuis DH, Rea D, van Tongeren J, de Jong J, Bres SA, et al. Expression of the serpin serine protease inhibitor 6 protects dendritic cells against cytotoxic T lymphocyte–induced apoptosis. Differential modulation by T helper type 1 and type 2 cells. J Exp Med. 2001;194:657–68.
63. Wurtzen PA, Nissen MH, Claesson MH. Maturation of dendritic cells by recombinant human CD40L-trimer leads to a homogeneous cell population with enhanced surface marker expression and increased cytokine production. Scand J Immunol. 2001;53:579–87.
64. Jyothi MD, Khar A. Regulation of CD40L expression on natural killer cells by interleukin-12 and interferon gamma: its role in the elicitation of an effective antitumor immune response. Cancer Immunol Immunother. 2000;49:563–72.
65. Hill SC, Youde SJ, Man S, Teale GR, Baxendale AJ, Hislop A, et al. Activation of Cl carcinoma cells facilitates CTL responses and augments chemotherapy-induced apoptosis. J Immunol. 2005;174:41–50.
66. Alexandroff AB, Jackson AM, Paterson T, Haley JL, Ross JA, Longo DL, et al. Role for CD40-CD40 ligand interactions in the immune response to solid tumours. Mol Immunol. 2000;37:515–26.
67. Buhtoiarov IN, Lum HD, Berke G, Sondel PM, Rakhmilevich AL. Synergistic activation of macrophages via CD40 and TLR9 results in T cell independent antitumor effects. J Immunol. 2006;176:309–18.
68. Küppers R. Molecular biology of Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program. 2009:491-6.
69. Ghia P, Transidico P, Veiga JP, Schaniel C, Sallusto F, Matsushima K, et al. Chemoattractants MDC and TARC are secreted by malignant B-cell precursors following CD40 ligation and support the migration of leukemia-specific T cells. Blood. 2001;98:533–40.
70. Sokolowska-Wojdylo M, Wenzel J, Gaffal E, Lenz J, Speuser P, Erdmann S, et al. Circulating clonal CLA(+) and CD4(+) T cells in Sezary syndrome express the skin-homing chemokine receptors CCR4 and CCR10 as well as the lymph node-homing chemokine receptor CCR7. Br J Dermatol. 2005;152:258–64.
71. Szocinski JL, Khaled AR, Hixon J, Halverson D, Funakoshi S, Fanslow WC, et al. Activation-induced cell death of aggressive histology lymphomas by CD40 stimulation: induction of bax. Blood. 2002;100:217–23.
72. Baxendale AJ, Dawson CW, Stewart SE, Mudaliar V, Reynolds G, Gordon J, et al. Constitutive activation of the CD40 pathway promotes cell transformation and neoplastic growth. Oncogene. 2005;24:7913–23.
73. Tong AT, Papayoti MH, Netto G, Armstrong DT, Ordonez G, Lawson JM, et al. Growth-inhibitory effects of CD40 ligand (CD154) and its endogenous expression in human breast cancer. Clin Cancer Res. 2001;7:691–703.
74. Georgopoulos NT, Merrick A, Scott N, Selby PJ, Melcher A, Trejdosiewicz LK. CD40-mediated death and cytokine secretion in colorectal cancer: a potential target for inflammatory tumour cell killing. Int J Cancer. 2007;15:1373–81.
75. Schwabe RF, Schnabl B, Kweon YO, Brenner DA. CD40 activates NF-jB and c-Jun N-terminal kinase and enhances chemokine secretion on activated human hepatic stellate cells. J Immunol. 2001;166:6812–9.
76. Loro LL, Ohlsson M, Vintermyr OK, Liavaag PG, Jonsson R, Johannessen AC. Maintained CD40 and loss of polarized CD40 ligand expression in oral squamous cell carcinoma. Anticancer Res. 2001;21:113–7.
77. Von Leoprechting A, van der Bruggen P, Pahl HL, Aruffo A, Simon JC. Stimulation of CD40 on immunogenic human malignant melanomas augments their cytotoxic T lymphocyte-mediated lysis and induces apoptosis. Cancer Res. 1999;59:1287–94.
78. Prigione I, Corrias MV, Airoldi I, Raffaghello L, Morandi F, Bocca P, et al. Immunogenicity of human neuroblastoma. Ann N Y Acad Sci. 2004;1028:69–80.
79. Georgopoulos NT, Steele LP, Thomson MJ, Selby PJ, Southgate J, Trejdosiewicz LK. A novel mechanism of CD40-induced apoptosis of carcinoma cells involving TRAF3 and JNK/AP-1 activation. Cell Death Differ. 2006;13:1789–801.
80. Bugajska U, Georgopoulos NT, Southgate J, Johnson PW, Graber P, Gordon J, et al. The effects of malignant transformation on susceptibility of human urothelial cells to CD40-mediated apoptosis. J Natl Cancer Inst. 2002;94:1381–95.
81. Young LS, Eliopoulos AG, Gallagher NJ, Dawson CW. CD40 and epithelial cells: across the great divide. Immunol Today. 1998;19:502–6.
82. Aruffo A, Farrington M, Hollenbaugh D, Li X, Milatovich A, Nonoyama S, et al. The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked hyper-IgM syndrome. Cell. 1993;72:291–300.
83. Law CL, Grewal IS. Therapeutic interventions targeting CD40L (CD154) and CD40: the opportunities and challenges. Therapeutic targets of the TNF superfamily. Adv Exp Med Biol. 2009;647:8–36.
84. Hirano A, Longo DL, Taub DD, Ferris DK, Young LS, Eliopoulos AG, et al. Inhibition of human breast carcinoma growth by a soluble recombinant human CD40 ligand. Blood. 1999;93:2999–3007.
85. Wingett DG, Vestal RE, Forcier K, Hadjokas N, Nielson CP. CD40 is functionally expressed on human breast carcinomas: variable inducibility by cytokines and enhancement of Fas-mediated apoptosis. Breast Cancer Res Treat. 1998;50:27–36.
86. Iida T, Shiba H, Misawa T, Ohashi T, Eto Y, Yanaga Y. Immunogene therapy against colon cancer metastasis using an adenovirus vector expressing CD40 ligand. Surgery. 2010;148:925–35.
87. Feder-Mengus C, Schultz-Thater E, Oertli D, Marti WR, Heberer M, Spagnoli GC, et al. Nonreplicating recombinant vaccinia virus expressing CD40 ligand enhances APC capacity to stimulate specific CD4+ and CD8+ T cell responses. Hum Gene Ther. 2005;16:348–60.
88. Nakajima A, Kodama T, Morimoto S, Azuma M, Takeda K, Oshima H, et al. Antitumor effect of CD40 ligand: elicitation of local and systemic antitumor responses by IL-12 and B7. J Immunol. 1998;161:1901–7.
89. Okur FV, Yvon E, Biagi E, Dotti G, Carrum G, Heslop H, et al. Comparison of two CD40-ligand/interleukin-2 vaccines in patients with chronic lymphocytic leukemia. Cytotherapy. 2011;13:1128–39.
90. Biagi E, Rousseau R, Yvon E, Schwartz M, Dotti G, Foster A, et al. Responses to human CD40 ligand/human interleukin-2 autologous cell vaccine in patients with B-cell chronic lymphocytic leukemia. Clin Cancer Res. 2005;11:6916–23.
91. Takahashi S, Yotnda P, Rousseau R, Mei Z, Smith S, Rill D, et al. Transgenic expression of CD40L and interleukin-2 induces an autologous antitumor immune response in patients with non-Hodgkin’s lymphoma. Cancer Gene Ther. 2001;8:378–87.
92. Loskog AS, Fransson ME, Totterman TT. AdCD40L gene therapy counteracts T regulatory cells and cures aggressive tumors in an orthotopic bladder cancer model. Clin Cancer Res. 2005;11:8816–21.
93. Kipps TJ, Wierda WG, Cantwell MJ, Woods SJ, Rassenti LZ, Prussak CE. CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia. Blood. 2000;96:2917–24.
94. Kim SW, Lee HS, Yoon SK, Chung WC, Cho YS, Jeong JJ, et al. Expression of CD40 in gastric cancer and its effect on the apoptosis of gastric cancer cells. Korean J Gastroenterol. 2003;42:274–82.
95. Roselli M, Mineo TC, Basili S, Mariotti S, Martini F, Bellotti A, et al. Vascular endothelial growth factor (VEGF-A) plasma levels in non-small cell lung cancer: relationship with coagulation and platelet activation markers. Thromb Haemost. 2003;89:177–84.
96. Dzojic H, Loskog A, Tötterman TH, Essand M. Adenovirus-mediated CD40 ligand therapy induces tumor cell apoptosis and systemic immunity in the TRAMP-C2 mouse prostate cancer model. Prostate. 2006;66:831–8.
97. Gomes EM, Rodrigues MS, Phadke AP, Butcher LD, Starling C, Chen S, et al. Antitumor activity of an oncolytic adenoviral-CD40 ligand (CD154) transgene construct in human breast cancer cells. Clin Cancer Res. 2009;15:1317–25.
98. Hernandez-Alcoceba R, Pihalja M, Qian D, Clarke MF. New oncolytic adenoviruses with hypoxia- and estrogen receptor-regulated replication. Hum Gene Ther. 2002;13:1737–50.
99. Vardouli L, Lindqvist C, Vlahou K, Loskog AS, Eliopoulos AG. Adenovirus delivery of human CD40 ligand gene confers direct therapeutic effects on carcinomas. Cancer Gene Ther. 2009;16:848–60.
100. Kikuchi T, Moore MAS, Crystal RG. Dendritic cells modified to express CD40 ligand elicit therapeutic immunity against preexisting murine tumors. Blood. 2000;1:91–9.
101. Tai YT, Li XF, Catley L, Coffey R, Breitkreutz I, Bae J, et al. Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications. Cancer Res. 2005;65:11712–20.
102. Haswell LE, Glennie MJ, Al-Shamkhani A. Analysis of the oligomeric requirement for signaling by CD40 using soluble multimeric forms of its ligand, CD154. Eur J Immunol. 2001;31:3094–100.
103. Stone GW, Barzee S, Snarsky V, Kee K, Spina CA, Yu XF, et al. Multimeric soluble CD40 ligand and GITR ligand as adjuvants for human immunodeficiency virus DNA vaccines. J Virol. 2006;80:1762–72.
104. Naito M, Hainz U, Burkhardt UE, Fu B, Ahove D, Stevenson KE, et al. CD40L-Tri, a novel formulation of recombinant human CD40L that effectively activates B cells. Cancer Immunol Immunother. 2013;62:347–57.